Notice2024-21363
National Cancer Institute; Notice of Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 19, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 182 (Thursday, September 19, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 182 (Thursday, September 19, 2024)]
[Notices]
[Page 76863]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-21363]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Institute Clinical Trials and Translational Research Advisory
Committee.
This will be a hybrid meeting held in-person and virtually and will
be open to the public. Individuals who plan to attend in-person or view
the virtual meeting and need special assistance or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting. The meeting can be accessed from the NIH
Videocast at the following link: <a href="https://videocast.nih.gov/">https://videocast.nih.gov/</a>.
Name of Committee: National Cancer Institute Clinical Trials and
Translational Research Advisory Committee.
Date: November 6, 2024.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: Strategic Discussion of NCI's Clinical and Translational
Research Programs.
Place: National Cancer Institute, 9609 Medical Center Drive,
East Wing, Conference Room TE406/408/410, Rockville, MD 20850 (In
Person and Virtual Meeting).
Contact Person: Sheila A. Prindiville, M.D., M.P.H., Director,
Coordinating Center for Clinical Trials, National Cancer Institute,
National Institutes of Health, 9609 Medical Center Drive, Room
6W136, Rockville, MD 20850, 240-276-6173, <a href="/cdn-cgi/l/email-protection#aadad8c3c4cec3dcd9eac7cbc3c684c4c3c284cdc5dc"><span class="__cf_email__" data-cfemail="1464667d7a707d62675479757d783a7a7d7c3a737b62">[email protected]</span></a>.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NCI-Shady Grove campus. All
visitors will be asked to show one form of identification (for
example, a government-issued photo ID, driver's license, or
passport) and to state the purpose of their visit.
Information is also available on the Institute's/Center's home
page: <a href="http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm">http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm</a>, where an
agenda and any additional information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: September 13, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2024-21363 Filed 9-18-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 19, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.